Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554072 | 0.89 | HRH3 (0.48) | GPR139KCNH2HRH3MAPTLMNA | |
| SCHEMBL1554095 | 0.88 | GPR139 (0.48) | GPR139KCNH2HRH3MAPTLMNA | |
| SCHEMBL4579481 | 0.84 | ALDH1A1 (0.59) | KCNH2HRH3MAPTLMNAALDH1A1 | |
| SCHEMBL1554244 | 0.83 | GPR139 (0.46) | GPR139KCNH2HRH3MAPTLMNA | |
| SCHEMBL452482 | 0.83 | GPR139 (0.48) | GPR139KCNH2HRH3MAPTLMNA | |
| SCHEMBL1552479 | 0.79 | HRH3 (0.47) | KCNH2HRH3LMNAALDH1A1PDE10A | |
| SCHEMBL1553112 | 0.79 | PDE10A (0.56) | GPR139KCNH2HRH3ALDH1A1RAB9A | |
| SCHEMBL1552456 | 0.79 | ALDH1A1 (0.47) | GPR139KCNH2HRH3MAPTALDH1A1 | |
| SCHEMBL452922 | 0.77 | KEAP1 (0.43) | GPR139KCNH2HRH3MAPTLMNA | |
| SCHEMBL1553986 | 0.77 | HRH3 (0.48) | GPR139KCNH2HRH3MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | claimed |
| EP-1521746-B1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-04-27 | — | — | EP | claimed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| US-8748440-B2 | Quinazolinone modulators of nuclear receptors | EXELIXIS, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1521746-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2003076418-A1 | QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070864-A1 | Quinazolinone Modulators Of Nuclear Receptors | NR1H4, NR1H2, NR1H3 | GPR139 546/4885KCNH2 4581/4885HRH3 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.